Bioactivity:

Nivolumab anti-PD-1) is a genetically engineered fully human immunoglobulin Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1PD-1PCD-1) with immune checkpoint inhibitory and antineopla

CAS nr:

946414-94-4

Purity:

98%

Molecular Weight:

146000

SMILES:

Formula:

Pathway:

Apoptosis,Immunology/Inflammation,Cell Cycle/Checkpoint

Target:

PD-1/PD-L1,PD-1/PD-L1,PD-1/PD-L1